Art. -Nr.: HY-A0122

Plicamycin

(Synonyms: Mithramycin A)

56 Cited Publications

Kundenbewertung

Based on 56 publication(s) in Google Scholar

Plicamycin (Mithramycin A) is a selective specificity protein 1 (Sp1) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein. Plicamycin inhibits GSTM2 promoter activity and protein expression.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.46%
CAS. Nr.: 18378-89-7
Formel: C₅₂H₇₆O₂₄
Molecular Weight:1085.15

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Plicamycin Chemical Structure

CAS. Nr.: 18378-89-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (56)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

GSTM2

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human A549 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human A549 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
A673	GI₅₀	46 nM Compound: 1; MTM	Growth inhibition of human A673 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human A673 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
DMS-114	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human DMS114 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human DMS114 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
DU-145	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human DU145 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human DU145 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
ES7	GI₅₀	46 nM Compound: 1; MTM	Growth inhibition of human ES7 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human ES7 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
ES8	GI₅₀	46 nM Compound: 1; MTM	Growth inhibition of human ES8 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human ES8 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
HCT-116	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human HCT116 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human HCT116 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
HeLa	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human HeLa cells incubated for 72 hrs by resazurin based assay Growth inhibition of human HeLa cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
LNCaP	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human LNCAP cells incubated for 72 hrs by resazurin based assay Growth inhibition of human LNCAP cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
PANC-1	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human PANC1 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human PANC1 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
PC-3	GI₅₀	83 nM Compound: 1; MTM	Growth inhibition of human PC3 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human PC3 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
Prostatic carcinoma cell	GI₅₀	48 nM Compound: 1; MTM	Growth inhibition of human prostate cancer cell cells lacking TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay Growth inhibition of human prostate cancer cell cells lacking TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
TC-32	GI₅₀	32 nM Compound: 1; MTM	Growth inhibition of human TC32 cells incubated for 72 hrs by resazurin based assay Growth inhibition of human TC32 cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
U-118-MG	GI₅₀	71 nM Compound: 1; MTM	Growth inhibition of human U118MG cells incubated for 72 hrs by resazurin based assay Growth inhibition of human U118MG cells incubated for 72 hrs by resazurin based assay	[PMID: 30114371]
VCaP	GI₅₀	41 nM Compound: 1; MTM	Growth inhibition of human VCaP cells overexpressing TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay Growth inhibition of human VCaP cells overexpressing TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay	[PMID: 30114371]

In Vitro

Plicamycin (Mith) decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. Plicamycin inhibits HEp-2 and KB cell growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Plicamycin leads to significant DNA fragmentation compared to untreated controls^[1].
Plicamycin (mithramycin A) (0-400 nM, 24 h) dose-dependently inhibited GSTM2 protein expression in BFTC 905 and 5637 cells; SP1 overexpression increased GSTM2 protein expression in BFTC 905 and 5637 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The antitumorigenic activity of Plicamycin (0.2 mg/kg/day) is determined in a xenograft model and observed reduction in tumor volume and weight. No significant mouse body weight loss is observed in Plicamycin-treatment groups, indicating that Plicamycin-associated toxicity is minimal. Plicamycin also increases TUNEL-positive cells in tumor xenografts. No notable intergroup differences are observed among organs, indicating no marked signs of systemic toxicity at the Plicamycin dose used in this study^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 18378-89-7
Appearance Solid
Molecular Weight 1085.15
Formel C₅₂H₇₆O₂₄
Color Yellow to brown
SMILES

O=C([C@H]([C@@]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)([H])C1)O[C@@](O[C@H](C)[C@H]2O)([H])C[C@H]2O[C@@](O[C@H](C)[C@@H]3O)([H])C[C@H]3O[C@@](O[C@H](C)[C@H]4O)([H])C[C@@]4(O)C)C(C1=CC5=CC(O[C@H](O[C@H](C)[C@H]6O)C[C@H]6O[C@@](O[C@H](C)[C@H]7O)([H])C[C@H]7O)=C(C)C(O)=C85)=C8O
Synonyms

Mithramycin A
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (56)

All Cell Imaging/StainingELISAIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Mol Cancer

AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity. [Abstract]

2024 Dec 20;23(1):275. PMID: 39702289

Plicamycin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Dec 20;23(1):275. [Abstract]

Plicamycin (PLICA, 5 µM, 4 or 16 h) decreased the ratio of nucleolar area to nuclear area in human osteosarcoma U2OS cells.

Plicamycin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Dec 20;23(1):275. [Abstract]

Mouse fibrosarcoma MCA205 cells treated with Plicamycin (50 µM) were subcutaneously inoculated (5 × 10⁵ cells) into one flank of C57Bl/6 mice, and tumor growth was inhibited.
Mol Cancer

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. [Abstract]

2022 Mar 18;21(1):77. PMID: 35303882
Cancer Res

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment. [Abstract]

2024 Sep 16;84(18):2985-3003. PMID: 38885318
Cancer Res

VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. [Abstract]

2024 Sep 16;84(18):2954-2967. PMID: 38809694

Plicamycin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Sep 16;84(18):2954-2967. [Abstract]

Treatment with Plicamycin (0.5 μM, 24 h) inhibited TGF-β1 secretion in KPC.luc and MT5 cells.
Nat Commun

Endothelial Sp1/Sp3 are essential to the effect of captopril on blood pressure in male mice. [Abstract]

2023 Sep 21;14(1):5891. PMID: 37735515

Plicamycin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 21;14(1):5891. [Abstract]

Mithramycin A (MITA, 0.4 mg/kg body weight, intraperitoneal injection, 3 weeks) increased systolic blood pressure (SBP) and mean blood pressure (MBP) in C57BL/6J mice.
Nat Commun

Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. [Abstract]

2023 Feb 9;14(1):731. PMID: 36759621
Acta Pharm Sin B

STK39 inhibits antiviral immune response by inhibiting DCAF1-mediated PP2A degradation. [Abstract]

2025 Mar;15(3):1535-1551. PMID: 40370558
Adv Sci (Weinh)

Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome. [Abstract]

2026 Apr;13(23):e18185. PMID: 41684293
Adv Sci (Weinh)

F-Box and Leucine-Rich Repeat Protein 4 (FBXL4) Maintains Sarcomere Integrity and Cardiac Function by Enhancing K48-Linked Ubiquitinated Degradation of Profilin-1 (PFN1). [Abstract]

2026 Mar;13(17):e16702. PMID: 41589689
Theranostics

FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape. [Abstract]

2022 Jan 1;12(2):842-858. PMID: 34976216
Protein Cell

Integrative analysis of transcriptome, DNA methylome and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy. [Abstract]

2024 May 23:pwae032. PMID: 38780967
Redox Biol

SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors. [Abstract]

2024 Aug 10:76:103304. PMID: 39153252
Cancer Lett

Pleckstrin-2 promotes tumour immune escape from NK cells by activating the MT1-MMP-MICA signalling axis in gastric cancer. [Abstract]

2023 Sep 28:572:216351. PMID: 37591356
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Cell Death Dis

Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. [Abstract]

2021 Oct 21;12(11):978. PMID: 34675191
Dev Cell

SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis. [Abstract]

2024 May 17:S1534-5807(24)00296-X. PMID: 38776924
Phytomedicine

Licochalcone A promotes SP1/DNA-PKcs-dependent NHEJ repair to prevent ferroptosis and attenuate hepatic ischemia-reperfusion injury. [Abstract]

2025 Dec 3:150:157650. PMID: 41365195
Neoplasia

Targeting the ELF1/EGFR/ERK positive feedback loop overcomes resistance to androgen receptor inhibition in AR-Vs positive prostate cancer. [Abstract]

2026 Aug:78:101324. PMID: 42263596
Cell Death Discov

GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy. [Abstract]

2025 Jun 6;11(1):268. PMID: 40480981
Cell Death Discov

FASN promotes lipid metabolism and progression in colorectal cancer via the SP1/PLA2G4B axis. [Abstract]

2025 Mar 28;11(1):122. PMID: 40148316
Cell Rep

Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation. [Abstract]

2025 Feb 5;44(2):115246. PMID: 39918960
Cell Rep

LHPP-mediated inorganic pyrophosphate hydrolysis-driven lysosomal acidification in astrocytes regulates adult neurogenesis. [Abstract]

2023 Aug 11;42(8):112975. PMID: 37573508
Cell Biol Toxicol

Chromatin accessibility of CD8 T cell differentiation and metabolic regulation. [Abstract]

2021 Jun;37(3):367-378. PMID: 32656717
Biochem Pharmacol

Mrps15/Mrps21 induced by Zhx1 protects mice from hypertensive heart disease by restoring mitochondrial translation. [Abstract]

2026 Sep;251(Pt 1):118081. PMID: 42162768
World J Gastroenterol

ICAM2 loss drives 5-fluorouracil resistance via TGF-β/Smad/SP1/PTN-dependent apoptosis evasion and macrophage remodeling in gastric cancer. [Abstract]

2026 Feb 7;32(5):115301. PMID: 41693979
Cancer Immunol Immunother

Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1. [Abstract]

2022 Feb;71(2):311-325. PMID: 34159436
Biofactors

SP1/CTR1-mediated oxidative stress-induced cuproptosis in intervertebral disc degeneration. [Abstract]

2024 Sep-Oct;50(5):1009-1023. PMID: 38599595
Int Immunopharmacol

4-Methylesculetin attenuates inflammatory pain via inhibition of Sp1-TRPV1 and inflammation related signaling pathways. [Abstract]

2025 Apr 16:152:114379. PMID: 40054325
Eur J Pharmacol

FADS1 inhibition protects retinal pigment epithelium cells from ferroptosis in age related macular degeneration. [Abstract]

2024 Dec 28:177227. PMID: 39736411
Int Immunopharmacol

PKCδ modulates SP1 mediated mitochondrial autophagy to exacerbate diacetylmorphine-induced ferroptosis in neurons. [Abstract]

2024 Oct 25;143(Pt 2):113468. PMID: 39490143
Cancers (Basel)

MerTK Is Regulated by Orphan Nuclear Receptor 4A1 (NR4A1) and NR4A2 in Colon Cancer Cells. [Abstract]

2026 Jun 18;18(12):1993. PMID: 42352525
FASEB J

The downregulation of HSP90-controlled CRALBP expression is associated with age-related vision attenuation. [Abstract]

2023 Mar;37(3):e22832. PMID: 36826429
J Cell Mol Med

Photobiomodulation therapy promotes the ATP-binding cassette transporter A1-dependent cholesterol efflux in macrophage to ameliorate atherosclerosis. [Abstract]

2021 Jun;25(11):5238-5249. PMID: 33951300
Sci Rep

SHP2 improves ovarian morphology and steroidogenic function in a rat PCOS model by modulating IRE1α/XBP1/NLRP3-mediated granulosa cell pyroptosis. [Abstract]

2026 Mar 21;16(1):14376. PMID: 41865134
Sci Rep

SHP1 and its downstream p38/SP1/PI3K/YAP/Notch-1 signaling in trophoblast cells suppressed the progression of Preeclampsia via inhibiting proliferation of SMCs. [Abstract]

2025 May 9;15(1):16205. PMID: 40346122
Cancer Res Treat

Hepatitis B Virus Core Protein Mediates the Upregulation of C5α Receptor 1 via NF-κB Pathway to Facilitate the Growth and Migration of Hepatoma Cells. [Abstract]

2021 Apr;53(2):506-527. PMID: 33197304
Biochim Biophys Acta Mol Cell Res

Inhibition of the Sp1/PI3K/AKT signaling pathway exacerbates doxorubicin-induced cardiomyopathy. [Abstract]

2025 Apr 15;1872(5):119960. PMID: 40246177
Mol Cell Biochem

Human umbilical cord mesenchymal stem cell exosomes promote elastin production and acute skin wound healing via TGFβ1-Smad pathway. [Abstract]

2025 Apr 9. PMID: 40202710
Toxicol Appl Pharmacol

Triptolide impairs glycolysis by suppressing GATA4/Sp1/PFKP signaling axis in mouse Sertoli cells. [Abstract]

2021 Aug 15:425:115606. PMID: 34087332
J Cancer

Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. [Abstract]

2022 Apr 11;13(7):2226-2237. PMID: 35517402
BMC Oral Health

Role of transglutaminase 2 in promoting biglycan synthesis in idiopathic gingival fibromatosis. [Abstract]

2024 Nov 21;24(1):1422. PMID: 39574071
Genes (Basel)

Novel Single Nucleotide Polymorphisms and Haplotype of MYF5 Gene Are Associated with Body Measurements and Ultrasound Traits in Grassland Short-Tailed Sheep. [Abstract]

2022 Mar 9;13(3):483. PMID: 35328037
Immunol Invest

Sp1 Controls the Basal Level of Interleukin-34 Transcription. [Abstract]

2023 Feb;52(2):224-240. PMID: 36562687

Plicamycin purchased from MedChemExpress. Usage Cited in: Immunol Invest. 2023 Feb;52(2):224-240. [Abstract]

Plicamycin (0, 50, 100, 200, 500 nM; 24 h) reduces IL-34 expression.
SSRN

2026 May 20.
bioRxiv

Mechanisms controlling the deposition and dynamics of histone variant H2BE. [Abstract]

2026 Apr 22:2026.04.20.719605. PMID: 42079300
Res Sq

2025 Dec 3.
Research Square Preprint

2025 Jan 11.
bioRxiv

2024 Nov 06.
SSRN

2024 Apr 6.
bioRxiv

2024 Jan 16.
Research Square Preprint

2023 Oct 11.
Research Square Print

2023 Mar 14.
Research Square Print

November 8th, 2022
Research Square Print

2020 May.
Research Square Preprint

2021 Nov.
Research Square Preprint

2021 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (92.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9215 mL

4.6077 mL

9.2153 mL

5 mM

0.1843 mL

0.9215 mL

1.8431 mL

10 mM

0.0922 mL

0.4608 mL

0.9215 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

HEp-2 cells and KB cells are cultured in DMEM 100 U/mL each of Penicillin and Streptomycin and 10% FBS for HEp-2 cells and 5% FBS for KB in a humidified atmosphere containing 5% CO₂ at 37°C. Equal numbers of cells are seeded and allowed to attach. At 50-60% confluence, cells are treated with DMSO or indicated concentrations of Plicamycin (50, 100, and 200 nM for HEp-2 cells; 20, 40, and 80 nM for KB cells). Cell viability is determined using CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kits. In brief, cells are seeded in 96-well plates and incubated with Plicamycin. After treatment, 30 µL MTS solution is added to each well and cells are incubated for 2 h at 37°C. MTS solution is analyzed using a microplate reader at 490 nm and 690 nm^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Female nude mice are used. KB cells are suspended in sterile PBS and injected subcutaneously into the right flank of mice. Mice are randomized into two groups containing five mice each and treated with 0.2 mg/kg/day of Plicamycin (i.p.) three times per week for 29 days. Control mice receive an equal volume of vehicle. After 29 days, bodies, organs and tumors are weighed and tumor volumes determined. Tumors are measured^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Choi ES, et al. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014 Nov 24;4:7162. [Content Brief]

[2]. Shen CH, et al. The suppressive role of phytochemical-induced glutathione S-transferase Mu 2 in human urothelial carcinoma cells. Biomed Pharmacother. 2022 Jul;151:113102. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9215 mL	4.6077 mL	9.2153 mL	23.0383 mL
	5 mM	0.1843 mL	0.9215 mL	1.8431 mL	4.6077 mL
	10 mM	0.0922 mL	0.4608 mL	0.9215 mL	2.3038 mL
	15 mM	0.0614 mL	0.3072 mL	0.6144 mL	1.5359 mL
	20 mM	0.0461 mL	0.2304 mL	0.4608 mL	1.1519 mL
	25 mM	0.0369 mL	0.1843 mL	0.3686 mL	0.9215 mL
	30 mM	0.0307 mL	0.1536 mL	0.3072 mL	0.7679 mL
	40 mM	0.0230 mL	0.1152 mL	0.2304 mL	0.5760 mL
	50 mM	0.0184 mL	0.0922 mL	0.1843 mL	0.4608 mL
	60 mM	0.0154 mL	0.0768 mL	0.1536 mL	0.3840 mL
	80 mM	0.0115 mL	0.0576 mL	0.1152 mL	0.2880 mL

Keywords

Plicamycin

56 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Plicamycin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Food-Sourced Compound Library

Targeted Diversity Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Plicamycin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (56)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Plicamycin Related Classifications

HY-A0122 Related Classifications